STOCK TITAN

[SCHEDULE 13G/A] Adverum Biotechnologies, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Franklin Resources, Inc., together with principal shareholders Charles B. Johnson and Rupert H. Johnson, Jr., filed Amendment No. 1 to Schedule 13G covering Adverum Biotechnologies (ADVM) as of 30 Jun 2025.

  • Beneficial ownership: 0 shares; 0.0 % of the common stock.
  • Sole or shared voting power: none.
  • The group therefore certifies ownership of “<5 %” and is no longer a reporting 5 % holder.
  • Signatures executed 01 Aug 2025 by Assistant Secretary Thomas C. Mandia under powers of attorney.

The filing, made under Schedule 13G Rule 13d-1, indicates a complete exit by a previously significant institutional investor. No financial results, transaction details or strategic commentary are provided.

Franklin Resources, Inc., insieme ai principali azionisti Charles B. Johnson e Rupert H. Johnson, Jr., ha presentato la Modifica n. 1 al Schedule 13G relativa a Adverum Biotechnologies (ADVM) al 30 giugno 2025.

  • Possesso effettivo: 0 azioni; 0,0% del capitale sociale.
  • Potere di voto esclusivo o condiviso: nessuno.
  • Il gruppo certifica quindi una proprietà inferiore al “5%” e non è più un azionista soggetto a segnalazione per il 5%.
  • Le firme sono state apposte il 1° agosto 2025 dall’Assistente Segretario Thomas C. Mandia in virtù di procure.

La comunicazione, effettuata ai sensi della Regola 13d-1 del Schedule 13G, indica un’uscita completa da parte di un investitore istituzionale precedentemente rilevante. Non sono forniti risultati finanziari, dettagli sulle transazioni o commenti strategici.

Franklin Resources, Inc., junto con los principales accionistas Charles B. Johnson y Rupert H. Johnson, Jr., presentó la Enmienda N° 1 al Schedule 13G referente a Adverum Biotechnologies (ADVM) a fecha 30 de junio de 2025.

  • Propiedad beneficiaria: 0 acciones; 0,0% del capital social.
  • Poder de voto único o compartido: ninguno.
  • El grupo certifica por tanto una propiedad inferior al “5%” y deja de ser un accionista reportable del 5%.
  • Las firmas fueron ejecutadas el 1 de agosto de 2025 por el Secretario Asistente Thomas C. Mandia bajo poderes notariales.

La presentación, realizada bajo la Regla 13d-1 del Schedule 13G, indica una salida completa de un inversor institucional previamente significativo. No se proporcionan resultados financieros, detalles de transacciones ni comentarios estratégicos.

Franklin Resources, Inc.는 주요 주주인 Charles B. JohnsonRupert H. Johnson, Jr.와 함께 Adverum Biotechnologies (ADVM)에 관한 Schedule 13G의 수정안 1호를 2025년 6월 30일 기준으로 제출했습니다.

  • 실질 소유: 0주; 보통주 0.0%.
  • 단독 또는 공동 의결권: 없음.
  • 따라서 그룹은 “5% 미만” 소유를 인증하며 더 이상 5% 보고 대상 주주가 아닙니다.
  • 서명은 2025년 8월 1일 대리 비서 Thomas C. Mandia가 위임장에 따라 수행했습니다.

Schedule 13G 규칙 13d-1에 따라 제출된 이 문서는 이전에 중요한 기관 투자자가 완전히 철수했음을 나타냅니다. 재무 결과, 거래 세부사항 또는 전략적 언급은 제공되지 않았습니다.

Franklin Resources, Inc., ainsi que les principaux actionnaires Charles B. Johnson et Rupert H. Johnson, Jr., ont déposé l'Amendement n°1 au Schedule 13G concernant Adverum Biotechnologies (ADVM) au 30 juin 2025.

  • Détention effective : 0 actions ; 0,0 % du capital social.
  • Pouvoir de vote exclusif ou partagé : aucun.
  • Le groupe certifie ainsi une propriété inférieure à « 5 % » et n'est plus un actionnaire déclarant au seuil de 5 %.
  • Les signatures ont été apposées le 1er août 2025 par le secrétaire adjoint Thomas C. Mandia en vertu de procurations.

Le dépôt, effectué conformément à la règle 13d-1 du Schedule 13G, indique une sortie totale d'un investisseur institutionnel auparavant significatif. Aucun résultat financier, détail de transaction ou commentaire stratégique n'est fourni.

Franklin Resources, Inc. hat zusammen mit den Hauptaktionären Charles B. Johnson und Rupert H. Johnson, Jr. die Änderung Nr. 1 zum Schedule 13G für Adverum Biotechnologies (ADVM) zum Stichtag 30. Juni 2025 eingereicht.

  • Wirtschaftliches Eigentum: 0 Aktien; 0,0 % des Stammkapitals.
  • Alleinige oder gemeinsame Stimmrechte: keine.
  • Die Gruppe bestätigt damit einen Besitz von unter „5 %“ und ist nicht länger ein meldepflichtiger 5 %-Aktionär.
  • Die Unterschriften wurden am 1. August 2025 vom Assistant Secretary Thomas C. Mandia aufgrund von Vollmachten geleistet.

Die Einreichung gemäß Schedule 13G Regel 13d-1 weist auf einen vollständigen Ausstieg eines zuvor bedeutenden institutionellen Investors hin. Es werden keine finanziellen Ergebnisse, Transaktionsdetails oder strategische Kommentare bereitgestellt.

Positive
  • None.
Negative
  • Franklin Resources, Inc. and its principal shareholders report 0 shares and 0 % ownership, confirming a full exit from ADVM.

Insights

TL;DR: Franklin Resources declares 0 % ADVM stake; removal of large holder can pressure sentiment and liquidity.

The amendment confirms that Franklin Resources and the Johnson family now hold zero ADVM shares and possess no voting or dispositive power. Their departure eliminates a once-material institutional backer, potentially reducing stable ownership and increasing free float. While the document gives no rationale, the disappearance of a concentrated holder often signals diminished conviction and could introduce supply overhang from prior sales. From a portfolio-allocation view, the change is negative for investor confidence, though impact depends on market absorption of earlier disposals.

TL;DR: Filing is regulatory housekeeping; confirms the filers are below 5 % threshold.

This Schedule 13G/A fulfills disclosure obligations once ownership falls under 5 %. It clarifies that neither Franklin Resources nor its principals influence ADVM governance, as they hold no voting rights. Procedurally, the statement cleans the record and removes them from future 13D/G amendments unless a new position is built. Governance impact is neutral beyond the transparency benefit.

Franklin Resources, Inc., insieme ai principali azionisti Charles B. Johnson e Rupert H. Johnson, Jr., ha presentato la Modifica n. 1 al Schedule 13G relativa a Adverum Biotechnologies (ADVM) al 30 giugno 2025.

  • Possesso effettivo: 0 azioni; 0,0% del capitale sociale.
  • Potere di voto esclusivo o condiviso: nessuno.
  • Il gruppo certifica quindi una proprietà inferiore al “5%” e non è più un azionista soggetto a segnalazione per il 5%.
  • Le firme sono state apposte il 1° agosto 2025 dall’Assistente Segretario Thomas C. Mandia in virtù di procure.

La comunicazione, effettuata ai sensi della Regola 13d-1 del Schedule 13G, indica un’uscita completa da parte di un investitore istituzionale precedentemente rilevante. Non sono forniti risultati finanziari, dettagli sulle transazioni o commenti strategici.

Franklin Resources, Inc., junto con los principales accionistas Charles B. Johnson y Rupert H. Johnson, Jr., presentó la Enmienda N° 1 al Schedule 13G referente a Adverum Biotechnologies (ADVM) a fecha 30 de junio de 2025.

  • Propiedad beneficiaria: 0 acciones; 0,0% del capital social.
  • Poder de voto único o compartido: ninguno.
  • El grupo certifica por tanto una propiedad inferior al “5%” y deja de ser un accionista reportable del 5%.
  • Las firmas fueron ejecutadas el 1 de agosto de 2025 por el Secretario Asistente Thomas C. Mandia bajo poderes notariales.

La presentación, realizada bajo la Regla 13d-1 del Schedule 13G, indica una salida completa de un inversor institucional previamente significativo. No se proporcionan resultados financieros, detalles de transacciones ni comentarios estratégicos.

Franklin Resources, Inc.는 주요 주주인 Charles B. JohnsonRupert H. Johnson, Jr.와 함께 Adverum Biotechnologies (ADVM)에 관한 Schedule 13G의 수정안 1호를 2025년 6월 30일 기준으로 제출했습니다.

  • 실질 소유: 0주; 보통주 0.0%.
  • 단독 또는 공동 의결권: 없음.
  • 따라서 그룹은 “5% 미만” 소유를 인증하며 더 이상 5% 보고 대상 주주가 아닙니다.
  • 서명은 2025년 8월 1일 대리 비서 Thomas C. Mandia가 위임장에 따라 수행했습니다.

Schedule 13G 규칙 13d-1에 따라 제출된 이 문서는 이전에 중요한 기관 투자자가 완전히 철수했음을 나타냅니다. 재무 결과, 거래 세부사항 또는 전략적 언급은 제공되지 않았습니다.

Franklin Resources, Inc., ainsi que les principaux actionnaires Charles B. Johnson et Rupert H. Johnson, Jr., ont déposé l'Amendement n°1 au Schedule 13G concernant Adverum Biotechnologies (ADVM) au 30 juin 2025.

  • Détention effective : 0 actions ; 0,0 % du capital social.
  • Pouvoir de vote exclusif ou partagé : aucun.
  • Le groupe certifie ainsi une propriété inférieure à « 5 % » et n'est plus un actionnaire déclarant au seuil de 5 %.
  • Les signatures ont été apposées le 1er août 2025 par le secrétaire adjoint Thomas C. Mandia en vertu de procurations.

Le dépôt, effectué conformément à la règle 13d-1 du Schedule 13G, indique une sortie totale d'un investisseur institutionnel auparavant significatif. Aucun résultat financier, détail de transaction ou commentaire stratégique n'est fourni.

Franklin Resources, Inc. hat zusammen mit den Hauptaktionären Charles B. Johnson und Rupert H. Johnson, Jr. die Änderung Nr. 1 zum Schedule 13G für Adverum Biotechnologies (ADVM) zum Stichtag 30. Juni 2025 eingereicht.

  • Wirtschaftliches Eigentum: 0 Aktien; 0,0 % des Stammkapitals.
  • Alleinige oder gemeinsame Stimmrechte: keine.
  • Die Gruppe bestätigt damit einen Besitz von unter „5 %“ und ist nicht länger ein meldepflichtiger 5 %-Aktionär.
  • Die Unterschriften wurden am 1. August 2025 vom Assistant Secretary Thomas C. Mandia aufgrund von Vollmachten geleistet.

Die Einreichung gemäß Schedule 13G Regel 13d-1 weist auf einen vollständigen Ausstieg eines zuvor bedeutenden institutionellen Investors hin. Es werden keine finanziellen Ergebnisse, Transaktionsdetails oder strategische Kommentare bereitgestellt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Franklin Resources, Inc.
Signature:/s/Thomas C. Mandia
Name/Title:Thomas C. Mandia, Assistant Secretary of Franklin Resources, Inc.
Date:08/01/2025
Charles B. Johnson
Signature:/s/Thomas C. Mandia
Name/Title:Attorney in Fact for Charles B. Johnson pursuant to Power of Attorney attached to this Schedule 13G
Date:08/01/2025
Rupert H. Johnson, Jr.
Signature:/s/Thomas C. Mandia
Name/Title:Attorney in Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney attached to this Schedule 13G
Date:08/01/2025

Comments accompanying signature: LIMITED POWER OF ATTORNEY FOR SECTION 13 AND 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O'Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: 1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. ("FRI") and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a "Reporting Entity"), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act"); and 2. seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and 3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing. The undersigned acknowledges that: 1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information; 2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable; 3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and 4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act. The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith. This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023. /s/CHARLES B. JOHNSON Signature Charles B. Johnson Print Name LIMITED POWER OF ATTORNEY FOR SECTION 13 AND 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O'Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: 1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. ("FRI") and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a "Reporting Entity"), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act"); and 2. seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and 3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing. The undersigned acknowledges that: 1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information; 2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable; 3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and 4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act. The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith. This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023. /s/RUPERT H. JOHNSON, JR. Signature Rupert H. Johnson, Jr. Print Name
Exhibit Information

Exhibit A: Joint Filing Agreement Exhibit B: Item 4 Ownership Exhibit A: JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other of the attached statement on Schedule 13G and to all amendments to such statement and that such statement and all amendments to such statement are made on behalf of each of them. IN WITNESS WHEREOF, the undersigned have executed this agreement on the date of the signing of this filing. Franklin Resources, Inc. Charles B. Johnson Rupert H. Johnson, Jr. By: /s/THOMAS C. MANDIA Assistant Secretary of Franklin Resources, Inc. Attorney-in-Fact for Charles B. Johnson pursuant to Power of Attorney attached to this Schedule 13G Attorney-in-Fact for Rupert H. Johnson, Jr. pursuant to Power of attached to this Schedule 13G Exhibit B: Item 4 Ownership The securities reported herein are beneficially owned by one or more open or closed end investment companies or other managed accounts that are investment management clients of investment managers that are direct and indirect subsidiaries (each, an "Investment Management Subsidiary" and, collectively, the "Investment Management Subsidiaries") of Franklin Resources Inc. ("FRI"), including the Investment Management Subsidiaries listed in this Item 4. When an investment management contract (including a sub advisory agreement) delegates to an Investment Management Subsidiary investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, FRI treats the Investment Management Subsidiary as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies otherwise. Accordingly, each Investment Management Subsidiary reports on Schedule 13G that it has sole investment discretion and voting authority over the securities covered by any such investment management agreement, unless otherwise noted in this Item 4. As a result, for purposes of Rule 13d-3 under the Act, the Investment Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners of the securities reported in this Schedule 13G. Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34-39538 (January 12, 1998) (the "1998 Release") relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by each of FRI's affiliates whose ownership of securities is disaggregated from that of FRI in accordance with the 1998 Release ("FRI Disaggregated Affiliates") are exercised independently from FRI and from all other Investment Management Subsidiaries (FRI, its affiliates and the Investment Management Subsidiaries other than FRI Disaggregated Affiliates are collectively, "FRI Aggregated Affiliates"). Furthermore, internal policies and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand, FRI establish informational barriers that prevent the flow among, on the one hand, FRI Disaggregated Affiliates (including preventing the flow between such entities), and, on the other hand, the FRI Aggregated Affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, FRI Disaggregated Affiliates report the securities over which they hold investment and voting power separately from the FRI Aggregated Affiliates for purposes of Section 13 of the Act. Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") may each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI (see FRI's Proxy Statement-Stock Ownership of Certain Beneficial Owners). FRI and the Principal Shareholders may be deemed to be, for purposes of Rule 13d-3 under the Act, the beneficial owners of securities held by persons and entities for whom or for which FRI subsidiaries provide investment management services. The number of shares that may be deemed to be beneficially owned and the percentage of the class of which such shares are a part are reported in Items 9 and 11 of the cover page for FRI. FRI, the Principal Shareholders and each of the Investment Management Subsidiaries disclaim any pecuniary interest in any of such securities. In addition, the filing of this Schedule 13G on behalf of the Principal Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be construed as an admission that any of them is, and each of them disclaims that it is, the beneficial owner, as defined in Rule 13d-3, of any of the securities reported in this Schedule 13G. FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries believe that they are not a "group" within the meaning of Rule 13d-5 under the Act and that they are not otherwise required to attribute to each other the beneficial ownership of the securities held by any of them or by any persons or entities for whom or for which the Investment Management Subsidiaries provide investment management services.

FAQ

How many ADVM shares does Franklin Resources report owning?

The filing lists 0 shares, representing 0.0 % of the outstanding common stock.

What is the event date for this Schedule 13G/A on ADVM?

30 June 2025 is the date triggering the filing requirement.

Who are the reporting persons in this ADVM Schedule 13G/A?

Franklin Resources, Inc., Charles B. Johnson, and Rupert H. Johnson, Jr.

What voting or dispositive power do the filers retain?

They report no sole or shared voting or dispositive power over ADVM shares.

When was the filing signed and by whom?

Signed on 01 Aug 2025 by Thomas C. Mandia, Assistant Secretary, under power of attorney.

Why does this filing matter to ADVM investors?

It confirms that a previously significant institutional holder has completely exited, potentially affecting ownership structure and market sentiment.
Adverum Biotech

NASDAQ:ADVM

ADVM Rankings

ADVM Latest News

ADVM Latest SEC Filings

ADVM Stock Data

48.47M
16.72M
13.1%
79.54%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
REDWOOD CITY